Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation

NCT03821519 is registered in ClinicalTrials.gov with A.O. Ospedale Papa Giovanni XXIII as lead sponsor.

NCT NCT03821519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03821519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation
Lead sponsor
A.O. Ospedale Papa Giovanni XXIII
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 13, 2019
Completion date
May 31, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed hematologic malignancy